ClinicalTrials.gg
RecruitingNCT07081048Updated Jul 23, 2025

Pain and Comfort Levels During Heel Stick Blood Sampling in Newborns

An interventional study of Buzzy®.Group and ShotBlocker Group in Newborn, sponsored by Tarsus University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 1 Day to 1 Month, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Tarsus University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 4 months after the study started (first participant enrolled Mar 2025, registered Jul 2025).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
1 Day to 1 Month
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Pain by Tarsus University — 7 open to participants now, 8 under way, none of them phase 3. Pain · Tarsus University.

Planned enrollment
Largest of 23
159 · median 90
Started
2025
with 1 other
No phase
23 of 23
7 open now
Registered
13th of 23
by date

Among the 23 studies in Pain by Tarsus University, this one has the largest planned enrollment, is one of 2 that started in 2025, is one of 23 with no phase, and was the 13th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

7 of the 23 studies in Pain by Tarsus University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 1 Day to 1 Month · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Pain by Tarsus University, or all of them as a file.
02

Study summary

Aim: The study was designed to determine the effect of Buzzy® and Shotbloker® application on pain and comfort levels in newborns during heel pricking. Method:The study was a randomised controlled trial. The study sample consisted of 159 newborns (Buzzy: 53, Shotbloker: 53, control: 53) who had heel pricks between March 2025 and December 2025 at the Samandağ State Hospital Neonatal Care Unit. The data collection tools used will be the Newborn Information Form, the Newborn Pain Scale, the Newborn Comfort Behaviour Scale, and the Buzzy® and Shotbloker® devices. In the intervention group, the Buzzy® and Shotbloker® devices will be applied before and after heel pricking, while the control group will receive routine care. The infants' pain and comfort levels will be assessed by the nurse before and after the procedure.

Read the detailed description

The study was designed as a randomised controlled trial to determine the effect of Buzzy® and Shotbloker® application on pain and comfort levels in newborns during heel prick blood sampling.

Materials and Methods Setting After obtaining ethical committee approval, the study will be conducted with babies admitted to the Neonatal Unit of Samandağ State Hospital between March and December 2025.

Sample According to the power analysis performed for the sample size, the power of the sample was calculated using the G*Power 3.1 programme in line with the literature. With a Type I error rate of 0.05 and a test power of 0.80 (α = 0.05, 1-β = 0.80), the minimum sample size (with 53 newborns in each group) was calculated to be 159.

Data Collection In the study, babies brought to the Neonatal Unit for heel prick blood sampling will first be evaluated according to the sampling criteria, and those who do not meet the criteria will be excluded from the study. The nurse researcher herself will collect the data, evaluate it using the NIPS pain scale and the Neonatal Comfort Behaviour Scale, collect the heel blood, and administer the Buzzy® and Shotbloker® applications. To ensure consistency in the application, heel blood will be collected from the left lateral foot of all infants included in the study by the same nurse.

Application Before the heel prick procedure, the room will be well lit and warm to ensure that the babies are comfortable. Babies in the Buzzy, Shotbloker, and control groups who meet the sample criteria will first be examined by a paediatrician, and if there are no contraindications for heel pricking, their parents will be informed about the study and their verbal and written consent will be obtained, after which the data collection form will be completed. The 'Baby Information Form' will be completed by the researcher before the heel pricking procedure. Immediately afterwards, the infant's physiological parameters (pulse, SpO2) will be measured, and the infant's pain and comfort will be assessed by the researcher using the NIPS Scale and YDKÖ. All infants participating in the study will be held in their mothers' arms during the heel prick procedure.

Before taking blood, the nurse will clean the skin with 70% isopropyl alcohol and wait for it to dry. Blood will be taken from each baby using a single sterile lancet, and the first drop of blood will be wiped away. Then, a blood sample will be taken from one side of the Guthrie card, covering the entire marked area. The blood sample will be taken so that bloodstains of equal size are visible on both sides of the blood collection paper. In this way, each of the five marked areas will be filled. During blood collection, the blood collection paper will not be pressed, and the heel will not be squeezed excessively to prevent haemolysis or dilution (thinning) of the blood with tissue fluid. All heel blood samples will be collected on standard blood sample paper containing five circles. After heel blood collection, the researcher will measure the physiological parameters of the babies in the Buzzy group, Shotbloker group, or control group a second time and record their pain and comfort assessments.

STATISTICAL ANALYSIS The data obtained within the scope of the research will be evaluated using the Statistical Package For Social Science (SPSS) 22.0 software package. The Chi-square Fisher's exact test will be used to determine the homogeneity between groups, the Independent Groups t-test will be used to determine whether the difference between groups is statistically significant, and the One-Way Analysis of Variance will be used to determine which group the difference originates from using the Bonferroni test.

One-Way Analysis of Variance will be used to determine whether the difference is statistically significant between groups, and the Bonferroni test will be used to determine which group the difference originates from. A significance level of 0.05 will be used, and if p\<0.05, a significant difference will be determined, and if p>0.05, no significant difference will be determined.

03

Conditions studied

  • Newborn

Browse trials for

Keywords

  • pain
  • confort
  • Buzzy
  • Shotbloker
04

Who can participate

Ages eligible
1 Day to 1 Month
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The baby must be full-term (38-42 weeks),
  • No analgesic administration up to 8 hours prior to the procedure,
  • No pain prior to the procedure,
  • No chronic or metabolic disease,
  • Born at least 24 hours prior,
  • Being in the hospital during the study period

Exclusion criteria

Exclusion Criteria:

  • The baby is not full-term,
  • Analgesic medication has been administered within 8 hours prior to the procedure,
  • The baby has a chronic or metabolic disease,
  • The baby requires oxygen support,
  • The baby cannot be fed orally,
  • The baby is not in the hospital on the dates the study will be conducted and the parents do not agree to participate in the study.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
159 participants (estimated)

Study arms

  • Experimental
    Buzzy® Group

    The ice pack, which has been removed from the deep freezer in advance, should be left at room temperature for 10 minutes, and the hole in the ice pack should be placed on the hook behind the Buzzy®. Buzzy® will be placed on the lateral side of the left heel and activated for 30 seconds. After 30 seconds, Buzzy® will be pulled up 1 centimetre (cm), and the heel will be punctured with a sterile lancet to collect blood on the Guthrie card. After the heel blood collection procedure, Buzzy® will be pulled back to the punctured heel area and left for another 30 seconds.

    Other: Buzzy®.Group

  • Experimental
    Shotbloker® Group

    ShotBlocker will be placed on the designated area for collecting the baby's heel blood. After ensuring that the protrusions of the ShotBlocker are in contact, pressure will be applied for 20 seconds. The heel will be punctured with a sterile lancet in the area designed for applying the ShotBlocker, and the ShotBlocker will be removed from the area. The blood collected will be collected on Guthrie paper.

    Other: ShotBlocker Group

  • No intervention
    Control Group

    Without any intervention or application to the heel area, the lateral side of the left foot will be punctured with a lancet of the same type, and heel blood sampling will be performed according to the clinic's routine practice. At the clinic, heel blood sampling is performed without any intervention, with the baby in the mother's arms.

Interventions

  • OtherBuzzy®.Group

    The ice pack, which has been removed from the deep freezer in advance, should be left at room temperature for 10 minutes, and the hole in the ice pack should be placed on the hook behind the Buzzy® will be placed on the lateral side of the left heel and activated for 30 seconds. After 30 seconds, Buzzy® will be pulled up 1 centimetre (cm), and the heel will be punctured with a sterile lancet to collect blood on the Guthrie card. After the heel blood collection procedure, Buzzy® will be pulled back to the punctured heel area and left for another 30 seconds.

  • OtherShotBlocker Group

    ShotBlocker will be placed on the designated area for collecting the baby's heel blood. After ensuring that the protrusions of the ShotBlocker are in contact, pressure will be applied for 20 seconds. The heel will be punctured with a sterile lancet in the area designed for applying the ShotBlocker, and the ShotBlocker will be removed from the area. The blood collected will be collected on Guthrie paper.

06

What researchers measure

Primary outcomes

  1. Neonatal Infant Pain Scale (NIPS)

    The Neonatal Infant Pain Scale (NIPS) was developed by Lawrence and colleagues in 1993. Its validity and reliability in Turkish were established by Akdovan in 1999 (81). Reliability values were found to be 0.83, 0.83, and 0.86 before, during, and after the procedure, respectively. The neonatal infant pain scale assesses facial expressions (0; relaxed, 1; distressed), crying (0; no crying, 1; whimpering, 2; loud crying), breathing (0; relaxed, 1; variable-irregular), arm (0; relaxed-free, 1; flexion-extension), legs (0; relaxed-free, 1; flexion-extension), and sleep-wakefulness (0; sleeping-awake and calm, 1; restless). Pain is assessed based on the total score. After observation, the scale is scored from a maximum of 7 to a minimum of 0. According to the scale, a score of 7 indicates the highest level of pain, while a score of 0 indicates the lowest level of pain. If the NIPS score is between 0 and 2, the pain is considered to be absent or mild. If the pain score is between 3 and 4, i

    Time frame: 1 day

  2. Newborn Information Form

    The information form has been prepared by reviewing the relevant literature and includes the baby's gestational age, gender, birth weight, birth length, mode of delivery, pre- and post-procedure physiological parameters (SPO2, pulse), NIPS Pain Score, and Newborn Comfort Behaviour Scale. The data collection form contains a total of 6 questions.

    Time frame: 1 day

  3. Newborn Comfort Behaviour Scale (NCBS)

    The scale was first developed in 1992 by Ambuel and colleagues to assess distress in patients receiving mechanical ventilator support in a paediatric intensive care unit. Later, in 2009, Van Dijk and colleagues revised the scale and established the validity and reliability of the COMFORTneo scale for measuring behaviour in newborns without physiological parameters. The COMFORTneo scale (NCBS) consists of 6 parameters (alertness, calmness/agitation, The COMFORTneo scale (YKDÖ) is a Likert-type scale consisting of six parameters (alertness, calmness/agitation, respiratory response, crying, body movements, facial tension, muscle tone). It is also a tool that provides nurses with numerical data to assess the comfort of newborns. The scale was revised in 2014 by Karaman et al. to establish its 'Turkish Validity and Reliability.' The lowest score on the scale is 6 and the highest score is 30, with high scores indicating that the baby is not comfortable. The Cronbach's alpha coefficient of t

    Time frame: 1 day

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • • Inal, S., Aydin Yilmaz, D., & Erdim, L. (2022). The effectiveness of swaddling and maternal holding applied during heel blood collection on pain level of healthy term newborns; randomized controlled trial. Early Child Development and Care, 192(13), 2066-2077.
  • Yavas S, Bulbul T, Topcu Gavas H. The effect on pain level and comfort of foot massages given by mothers to newborns before heel lancing: Double-blind randomized controlled study. Jpn J Nurs Sci. 2021 Oct;18(4):e12421. doi: 10.1111/jjns.12421. Epub 2021 Apr 20. PubMed 33880884 ↗
  • van der Burg S, Oerlemans A. Fostering caring relationships: Suggestions to rethink liberal perspectives on the ethics of newborn screening. Bioethics. 2018 Mar;32(3):171-183. doi: 10.1111/bioe.12425. PubMed 29442381 ↗
  • Sok P, Lupo PJ, Richard MA, Rabin KR, Ehli EA, Kallsen NA, Davies GE, Scheurer ME, Brown AL. Utilization of archived neonatal dried blood spots for genome-wide genotyping. PLoS One. 2020 Feb 21;15(2):e0229352. doi: 10.1371/journal.pone.0229352. eCollection 2020. PubMed 32084225 ↗
  • Shah SR, Kadage S, Sinn J. Trial of Music, Sucrose, and Combination Therapy for Pain Relief during Heel Prick Procedures in Neonates. J Pediatr. 2017 Nov;190:153-158.e2. doi: 10.1016/j.jpeds.2017.08.003. PubMed 29144240 ↗
  • Hummel P, Puchalski M, Creech SD, Weiss MG. Clinical reliability and validity of the N-PASS: neonatal pain, agitation and sedation scale with prolonged pain. J Perinatol. 2008 Jan;28(1):55-60. doi: 10.1038/sj.jp.7211861. Epub 2007 Oct 25. PubMed 18165830 ↗
  • Anand KJ, Hickey PR. Pain and its effects in the human neonate and fetus. N Engl J Med. 1987 Nov 19;317(21):1321-9. doi: 10.1056/NEJM198711193172105. No abstract available. PubMed 3317037 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2025, 9 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 9 months is close to that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Jul 23, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07081048
Lead sponsor
Tarsus University
Responsible party
Duygu Sonmez Duzkaya (Principal Investigator, Tarsus University) — Principal investigator
First posted
Jul 23, 2025
Start date
Mar 1, 2025
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Jul 23, 2025

Study contacts

Duygu Sönmez Düzkaya, PhD
Contact
duygusduzkaya@tarsus.edu.tr
+903246000033 ext. 2200
Gözde Özkan, BSC
Contact

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion